Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) COO Melissa Baird sold 58,750 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $19.57, for a total transaction of $1,149,737.50. Following the completion of the sale, the chief operating officer now owns 630,166 shares of the company’s stock, valued at approximately $12,332,348.62. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Melissa Baird also recently made the following trade(s):
- On Wednesday, September 4th, Melissa Baird sold 11,749 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total transaction of $172,122.85.
- On Tuesday, August 6th, Melissa Baird sold 16,784 shares of Hims & Hers Health stock. The shares were sold at an average price of $17.00, for a total transaction of $285,328.00.
Hims & Hers Health Trading Down 3.4 %
Shares of Hims & Hers Health stock traded down $0.67 during trading on Tuesday, hitting $18.77. 19,402,621 shares of the stock traded hands, compared to its average volume of 7,941,402. The firm has a market cap of $4.03 billion, a P/E ratio of -1,944.00 and a beta of 1.06. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $25.74. The stock’s fifty day simple moving average is $16.50 and its 200 day simple moving average is $17.31.
Institutional Investors Weigh In On Hims & Hers Health
Several hedge funds have recently bought and sold shares of HIMS. Renaissance Technologies LLC increased its stake in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after acquiring an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the last quarter. M&G Plc acquired a new stake in shares of Hims & Hers Health in the 1st quarter worth $8,232,000. Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after acquiring an additional 328,142 shares during the last quarter. Finally, State of Michigan Retirement System increased its stake in shares of Hims & Hers Health by 177.8% in the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after acquiring an additional 320,000 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have weighed in on the stock. TD Cowen raised their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Truist Financial boosted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Bank of America reduced their price objective on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, September 13th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.86.
Check Out Our Latest Stock Report on HIMS
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- What is a Secondary Public Offering? What Investors Need to Know
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What Are Dividend Contenders? Investing in Dividend Contenders
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- What is the Nikkei 225 index?
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.